This retrospective chart review analysis of data from the ELEVATE study investigated the impact of eculizumab treatment on the incidence of myasthenia gravis exacerbations and crises, associated healthcare resource utilization, and use of rescue therapy in clinical practice in patients with myasthenia gravis in the USA.

During eculizumab treatment, statistically significant reductions were observed in the rates of myasthenia gravis exacerbations and crises, in most measures of associated healthcare resource utilization, and in rescue therapy use, compared with the period before eculizumab treatment.

These results from clinical practice further support the beneficial effects and potential for a reduced socioeconomic burden associated with eculizumab treatment in patients with myasthenia gravis.